Báo cáo y học: "Drotrecogin alfa (activated): real-life use and outcomes for the UK" ppt

Báo cáo y học: "Drotrecogin alfa (activated): real-life use and outcomes for the UK" ppt

Báo cáo y học: "Drotrecogin alfa (activated): real-life use and outcomes for the UK" ppt

... paid for analyses for industry, including Eli Lilly and Company. All authors are employees of ICNARC. Authors' contributions KR conceived the study. EN coordinated the study. CW and DH performed ... manuscript. KR had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Ref...
Ngày tải lên : 13/08/2014, 10:20
  • 12
  • 302
  • 0
Báo cáo y học: "Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock" pot

Báo cáo y học: "Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock" pot

... that they have no competing interests. Authors' contributions HS and DNN conceived the study, and analyzed, interpreted and integrated the data. They also elaborated the manuscript. JT and ... manuscript. JT and LH performed and supervised the enrolment of patients in the study. JS performed the S100B assay. All authors read and approved the final version of...
Ngày tải lên : 13/08/2014, 20:21
  • 6
  • 269
  • 0
Báo cáo khoa học: "Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death" ppsx

Báo cáo khoa học: "Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death" ppsx

... for ADDRESS and PROWESS of 18.17% and 81.83%, respectively; method 2, a random effect model demonstrating a risk ratio using weights for ADDRESS and PROWESS of 45.35% and 54.65%, respectively; ... R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, et al., for the Administration of Drotrecogin alfa (activated) in Early Stage Severe Sepsis (ADDRESS...
Ngày tải lên : 13/08/2014, 03:20
  • 2
  • 211
  • 0
Báo cáo y học: "Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action" pps

Báo cáo y học: "Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action" pps

... other cytokines (e.g. IL-8, IL-6, and leukotriene inhibitory factor), proteases, and prostaglandin E 2 (PGE 2 ) [30]. Synthesis of the inflammatory cytokines IL-1 and TNF-α and expression of their ... chondrocytes or the articular cartilage surface in OA [29,31]. The activity of many MMPs increases in OA by either an increase in their own synthesis, an increased activation by th...
Ngày tải lên : 09/08/2014, 01:21
  • 14
  • 409
  • 0
Báo cáo khoa học: "Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies" ppt

Báo cáo khoa học: "Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies" ppt

... NoNoNoNoYesNoNoNoYesNo DrotAA-related 2 YesNoNoNoYesYesNoYesNoNo Disease category PF Yes Yes No No No Yes Yes No Yes Yes MEN No No Yes Yes Yes Yes No Yes Yes No MD YesNoYesNoNoYesNo NoNoYes Baseline ... infusion Day of event 1 117810UDUD Bleeding event ICH No No No Yes No Yes Yes Fatal No No No Yes No Yes No DrotAA related 2 No No No Yes No No No Disease category PF Yes Yes Yes Yes Yes No Yes...
Ngày tải lên : 12/08/2014, 22:21
  • 13
  • 361
  • 0
Báo cáo khoa học: "Drotrecogin alfa (activated): down and not out, but not really in eithe" ppt

Báo cáo khoa học: "Drotrecogin alfa (activated): down and not out, but not really in eithe" ppt

... any case, we believe that evidence for the routine use of DrotAA should be based on consistent clinical trials and should not depend on the use of a Letter Drotrecogin alfa (activated): down and ... estimate of the effect of DrotAA for any patient is the overall pooled result incorporating all patients. Interestingly, although the degree of between-study hetero- ge...
Ngày tải lên : 13/08/2014, 03:20
  • 2
  • 340
  • 0
Báo cáo khoa học: "Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death" pdf

Báo cáo khoa học: "Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death" pdf

... 2001 the United States and European drug regulatory agencies approved DrotAA for use in adult patients with severe sepsis and high risk of death, as defined by an Acute Physiology and Chronic ... greater in the DrotAA group both during the infusion (2.4% vs. 1.2%, P=0.02) and in the 28-day study period (3.9% vs. 2.2%, P=0.01) and were similar to rates seen in the...
Ngày tải lên : 13/08/2014, 03:20
  • 3
  • 295
  • 0
Báo cáo y học: " ncremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study" potx

Báo cáo y học: " ncremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study" potx

... uncertainty we used the extreme estimates for both the most positive and the most negative options for concomitant PPI therapy and NSAID use. The sec- ond approach was used to show the impact of varying ... complication for the group using con- comitant PPIs and the group not using concomitant PPIs. To test the robustness of the results, two approaches were used...
Ngày tải lên : 09/08/2014, 01:22
  • 7
  • 381
  • 0
Báo cáo y học: "Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al" doc

Báo cáo y học: "Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al" doc

... malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al. Arthritis Res Ther 2006, 8:111. Letter Response to commentary by Dixon and Silman on the systematic review and ... infliximab for partial responders [4]. Thus, not only are our findings applicable to clinical practice and biologically plausible, but they also fulfill the dose-effect criterion...
Ngày tải lên : 09/08/2014, 08:22
  • 2
  • 391
  • 0

Xem thêm

Từ khóa: